ABCA1 |
ATP binding cassette subfamily A member 1 |
- PPARA activates gene expression
- Defective ABCA1 causes Tangier disease
- HDL assembly
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
|
|
- Tangier disease
- Hypoalphalipoproteinemia
|
ACACA |
acetyl-CoA carboxylase alpha |
- ChREBP activates metabolic gene expression
- Biotin transport and metabolism
- Carnitine metabolism
- Activation of gene expression by SREBF (SREBP)
- Defective HLCS causes multiple carboxylase deficiency
- Fatty acyl-CoA biosynthesis
|
|
|
ADH1A |
alcohol dehydrogenase 1A (class I), alpha polypeptide |
- Abacavir metabolism
- RA biosynthesis pathway
- Ethanol oxidation
|
- NADH
- Fomepizole
- 4-Iodopyrazole
- N-Cyclopentyl-N-Cyclobutylformamide
|
|
AMFR |
autocrine motility factor receptor |
- N-glycan trimming in the ER and Calnexin/Calreticulin cycle
- ER Quality Control Compartment (ERQC)
|
|
|
AQP4 |
aquaporin 4 |
- Vasopressin regulates renal water homeostasis via Aquaporins
- Passive transport by Aquaporins
|
|
|
ARRB2 |
arrestin beta 2 |
- Activated NOTCH1 Transmits Signal to the Nucleus
- G alpha (s) signalling events
- Thrombin signalling through proteinase activated receptors (PARs)
- WNT5A-dependent internalization of FZD4
- Activation of SMO
- Activation of SMO
- MAP2K and MAPK activation
- Ub-specific processing proteases
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- Signaling downstream of RAS mutants
|
|
|
ASL |
argininosuccinate lyase |
|
- L-Arginine
- Argininosuccinate
- 2-(N-Morpholino)-Ethanesulfonic Acid
|
- Argininosuccinic aciduria (ARGINSA); Argininosuccinate lyase deficiency
|
ATF1 |
activating transcription factor 1 |
- CREB phosphorylation
- NGF-stimulated transcription
- NGF-stimulated transcription
|
|
- Clear cell sarcoma of soft tissue
|
ATF2 |
activating transcription factor 2 |
- Transcriptional activation of mitochondrial biogenesis
- HATs acetylate histones
- Circadian Clock
- Activation of the AP-1 family of transcription factors
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- NGF-stimulated transcription
- NGF-stimulated transcription
- Response of EIF2AK4 (GCN2) to amino acid deficiency
- Response of EIF2AK4 (GCN2) to amino acid deficiency
|
|
|
ATG16L1 |
autophagy related 16 like 1 |
- Macroautophagy
- Macroautophagy
|
|
|
BHLHE41 |
basic helix-loop-helix family member e41 |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Circadian Clock
|
|
|
BID |
BH3 interacting domain death agonist |
- Activation of BAD and translocation to mitochondria
- Activation and oligomerization of BAK protein
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Activation, translocation and oligomerization of BAX
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- Activation, myristolyation of BID and translocation to mitochondria
|
|
|
CABP1 |
calcium binding protein 1 |
|
|
|
CALM1 |
calmodulin 1 |
- CaMK IV-mediated phosphorylation of CREB
- CaMK IV-mediated phosphorylation of CREB
- Calmodulin induced events
- Cam-PDE 1 activation
- CaM pathway
- Platelet degranulation
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- PKA activation
- DARPP-32 events
- Synthesis of IP3 and IP4 in the cytosol
- Calcineurin activates NFAT
- Calcineurin activates NFAT
- eNOS activation
- Transcriptional activation of mitochondrial biogenesis
- Inactivation, recovery and regulation of the phototransduction cascade
- Inactivation, recovery and regulation of the phototransduction cascade
- Stimuli-sensing channels
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Ca2+ pathway
- Reduction of cytosolic Ca++ levels
- Sodium/Calcium exchangers
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of Adenylate Cyclase
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Smooth Muscle Contraction
- Smooth Muscle Contraction
- Activation of Ca-permeable Kainate Receptor
- Uptake and function of anthrax toxins
- VEGFR2 mediated vascular permeability
- VEGFR2 mediated cell proliferation
- Phase 0 - rapid depolarisation
- Ion homeostasis
- CLEC7A (Dectin-1) induces NFAT activation
- CLEC7A (Dectin-1) induces NFAT activation
- RHO GTPases activate IQGAPs
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Glycogen breakdown (glycogenolysis)
- Glycogen breakdown (glycogenolysis)
- Protein methylation
- Extra-nuclear estrogen signaling
- Loss of phosphorylation of MECP2 at T308
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Activation of RAC1 downstream of NMDARs
- Activation of RAC1 downstream of NMDARs
- Activation of AMPK downstream of NMDARs
- Long-term potentiation
- Long-term potentiation
- Signaling downstream of RAS mutants
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated IL10 synthesis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Chlorpromazine
- Cinchocaine
- Nicardipine
- Fluphenazine
- Isoflurane
- Trifluoperazine
- Loperamide
- Perphenazine
- Phenoxybenzamine
- Felodipine
- Melatonin
- Promethazine
- Pimozide
- Nifedipine
- Bepridil
- Calcium
- Aprindine
- 3''-(Beta-Chloroethyl)-2'',4''-Dioxo-3, 5''-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine
- 2-Methyl-2-Propanol
- N-Trimethyllysine
- N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
- Prenylamine
- Flunarizine
- (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
- Myristic acid
- Calcium Citrate
- Calcium Citrate
- Calcium Citrate
- Calcium Phosphate
- Calcium Phosphate
- Calcium Phosphate
|
|
CASQ2 |
calsequestrin 2 |
- Stimuli-sensing channels
- Ion homeostasis
|
- Calcium Citrate
- Calcium Phosphate
|
- Catecholaminergic polymorphic ventricular tachycardia
|
CAV1 |
caveolin 1 |
- Triglyceride catabolism
- eNOS activation
- NOSTRIN mediated eNOS trafficking
- Basigin interactions
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- VEGFR2 mediated vascular permeability
- Extra-nuclear estrogen signaling
- FOXO-mediated transcription of cell cycle genes
|
|
- Congenital generalized lipodystrophy (CGL)
|
CDC37 |
cell division cycle 37, HSP90 cochaperone |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Constitutive Signaling by EGFRvIII
- Downregulation of ERBB2 signaling
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
|
|
CLTB |
clathrin light chain B |
- Gap junction degradation
- Formation of annular gap junctions
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
|
CREBBP |
CREB binding protein |
- Regulation of gene expression by Hypoxia-inducible Factor
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- PPARA activates gene expression
- PPARA activates gene expression
- Formation of the beta-catenin:TCF transactivating complex
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- HATs acetylate histones
- Attenuation phase
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- CD209 (DC-SIGN) signaling
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- Activation of the TFAP2 (AP-2) family of transcription factors
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- Estrogen-dependent gene expression
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- FOXO-mediated transcription of cell death genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
|
- 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
|
- Rubinstein-Taybi syndrome
|
CREM |
cAMP responsive element modulator |
|
|
|
CSN3 |
casein kappa |
- Miscellaneous transport and binding events
|
|
|
CSNK2B |
casein kinase 2 beta |
- Synthesis of PC
- WNT mediated activation of DVL
- Condensation of Prometaphase Chromosomes
- Signal transduction by L1
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- Receptor Mediated Mitophagy
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN stability and activity
|
|
|
CTDP1 |
CTD phosphatase subunit 1 |
- Formation of RNA Pol II elongation complex
- Formation of the Early Elongation Complex
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Pausing and recovery of Tat-mediated HIV elongation
- Abortive elongation of HIV-1 transcript in the absence of Tat
- Tat-mediated HIV elongation arrest and recovery
- Tat-mediated elongation of the HIV-1 transcript
- HIV elongation arrest and recovery
- Pausing and recovery of HIV elongation
- RNA Polymerase II Pre-transcription Events
- TP53 Regulates Transcription of DNA Repair Genes
- RNA Polymerase II Transcription Elongation
|
|
|
DCPS |
decapping enzyme, scavenger |
- mRNA decay by 3' to 5' exoribonuclease
|
- 7-Methyl-Gpppa
- 7n-Methyl-8-Hydroguanosine-5'-Diphosphate
- N7-Methyl-Guanosine-5'-Monophosphate
- 7-methyl-guanosine-5'-triphosphate-5'-guanosine
- 5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine
- 5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine
- 5-[(1S)-1-(3-chlorophenyl)ethoxy]quinazoline-2,4-diamine
|
|
DELEC1 |
deleted in esophageal cancer 1 |
|
|
|
EEF1B2 |
eukaryotic translation elongation factor 1 beta 2 |
- Eukaryotic Translation Elongation
|
|
|
EIF2B2 |
eukaryotic translation initiation factor 2B subunit beta |
|
|
- Leukoencephalopathy with vanishing white matter; Vanishing white matter disease; Childhood ataxia with diffuse central nervous system hypomyelination (CACH); Cree leukoencephalopathy (CLE)
|
EIF2B5 |
eukaryotic translation initiation factor 2B subunit epsilon |
|
|
- Leukoencephalopathy with vanishing white matter; Vanishing white matter disease; Childhood ataxia with diffuse central nervous system hypomyelination (CACH); Cree leukoencephalopathy (CLE)
|
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
- mTORC1-mediated signalling
- Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
|
|
|
ERH |
ERH mRNA splicing and mitosis factor |
|
|
|
FGF1 |
fibroblast growth factor 1 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR1b ligand binding and activation
- FGFR3b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR2b ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR2 IIIa TM
- Signaling by FGFR3 point mutants in cancer
|
- Pentosan Polysulfate
- Amlexanox
- Heparin
- Sucrosofate
- Formic Acid
- O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- Naphthalene Trisulfonate
- Pazopanib
- 5-AMINO-NAPHTALENE-2-MONOSULFONATE
|
|
FGF2 |
fibroblast growth factor 2 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR1b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR2b ligand binding and activation
- FGFR3 mutant receptor activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR2 IIIa TM
- Signaling by FGFR3 point mutants in cancer
|
- Sucralfate
- Pentosan Polysulfate
- Sirolimus
- Heparin
- 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
- ABT-510
|
|
FKBP3 |
FKBP prolyl isomerase 3 |
|
|
|
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated MAPK activation
- Activation of the AP-1 family of transcription factors
- Interleukin-4 and Interleukin-13 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- Estrogen-dependent gene expression
- NGF-stimulated transcription
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Pseudoephedrine
- Nadroparin
|
|
GOT2 |
glutamic-oxaloacetic transaminase 2 |
- Degradation of cysteine and homocysteine
- Glyoxylate metabolism and glycine degradation
- Gluconeogenesis
- Aspartate and asparagine metabolism
- Glutamate and glutamine metabolism
|
- Pyridoxal Phosphate
- L-Aspartic Acid
- Glutamic Acid
- 4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate
|
|
GTF2A1 |
general transcription factor IIA subunit 1 |
- HIV Transcription Initiation
- RNA Polymerase II HIV Promoter Escape
- Transcription of the HIV genome
- RNA Polymerase II Pre-transcription Events
- RNA polymerase II transcribes snRNA genes
- RNA polymerase II transcribes snRNA genes
- RNA Polymerase II Promoter Escape
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase II Transcription Initiation
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Estrogen-dependent gene expression
|
|
|
GTF2A1L |
general transcription factor IIA subunit 1 like |
|
|
|
H1-2 |
H1.2 linker histone, cluster member |
- Apoptosis induced DNA fragmentation
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
|
|
|
HDAC1 |
histone deacetylase 1 |
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- G0 and Early G1
- p75NTR negatively regulates cell cycle via SC1
- Formation of the beta-catenin:TCF transactivating complex
- NOTCH1 Intracellular Domain Regulates Transcription
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- Deactivation of the beta-catenin transactivating complex
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
- NoRC negatively regulates rRNA expression
- SUMOylation of chromatin organization proteins
- Repression of WNT target genes
- Repression of WNT target genes
- Regulation of TP53 Activity through Acetylation
- G1/S-Specific Transcription
- RNA Polymerase I Transcription Initiation
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- Loss of MECP2 binding ability to 5mC-DNA
- Regulation of MECP2 expression and activity
- MECP2 regulates neuronal receptors and channels
- MECP2 regulates transcription of neuronal ligands
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Factors involved in megakaryocyte development and platelet production
|
- Arsenic trioxide
- Zinc
- Vorinostat
- Belinostat
- Pracinostat
- Romidepsin
- Panobinostat
- Fingolimod
- Mocetinostat
- Abexinostat
|
|
HDAC2 |
histone deacetylase 2 |
- p75NTR negatively regulates cell cycle via SC1
- NOTCH1 Intracellular Domain Regulates Transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
- NoRC negatively regulates rRNA expression
- SUMOylation of chromatin organization proteins
- Regulation of TP53 Activity through Acetylation
- RNA Polymerase I Transcription Initiation
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Regulation of MECP2 expression and activity
- MECP2 regulates neuronal receptors and channels
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
- Factors involved in megakaryocyte development and platelet production
|
- Lovastatin
- Theophylline
- Valproic Acid
- Aminophylline
- Oxtriphylline
- Vorinostat
- Belinostat
- Pracinostat
- Romidepsin
- Panobinostat
- Tixocortol
- Mocetinostat
|
|
HDAC6 |
histone deacetylase 6 |
- NOTCH1 Intracellular Domain Regulates Transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HSF1 activation
- Notch-HLH transcription pathway
- Cilium Assembly
- Transcriptional regulation by RUNX2
- RUNX2 regulates osteoblast differentiation
- Chaperone Mediated Autophagy
- Late endosomal microautophagy
- Aggrephagy
- Aggrephagy
|
- Vorinostat
- Belinostat
- Pracinostat
- Romidepsin
- Panobinostat
|
|
HMGA1 |
high mobility group AT-hook 1 |
- Integration of provirus
- 2-LTR circle formation
- Integration of viral DNA into host genomic DNA
- Autointegration results in viral DNA circles
- APOBEC3G mediated resistance to HIV-1 infection
- Vpr-mediated nuclear import of PICs
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
|
|
|
HMGA2 |
high mobility group AT-hook 2 |
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
|
|
|
HNRNPC |
heterogeneous nuclear ribonucleoprotein C |
- SUMOylation of RNA binding proteins
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
|
|
|
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- vRNP Assembly
- Regulation of actin dynamics for phagocytic cup formation
- eNOS activation
- Regulation of PLK1 Activity at G2/M Transition
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Sema3A PAK dependent Axon repulsion
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Anchoring of the basal body to the plasma membrane
- Constitutive Signaling by EGFRvIII
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Downregulation of ERBB2 signaling
- ESR-mediated signaling
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Constitutive Signaling by Overexpressed ERBB2
- Aggrephagy
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- Quercetin
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- Tanespimycin
- SNX-5422
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
- Copper
- Alvespimycin
|
|
HSP90B1 |
heat shock protein 90 beta family member 1 |
- Trafficking and processing of endosomal TLR
- Scavenging by Class A Receptors
- Scavenging by Class A Receptors
- ATF6 (ATF6-alpha) activates chaperone genes
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Interleukin-4 and Interleukin-13 signaling
- Post-translational protein phosphorylation
|
- Rifabutin
- 2-Chlorodideoxyadenosine
- Geldanamycin
- 1-Methoxy-2-(2-Methoxyethoxy)Ethane
- N-Ethyl-5'-Carboxamido Adenosine
- Radicicol
- METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE
- 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE
- Copper
|
|
HSPH1 |
heat shock protein family H (Hsp110) member 1 |
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- Regulation of HSF1-mediated heat shock response
|
|
|
IL16 |
interleukin 16 |
- Other interleukin signaling
|
|
|
KDM1A |
lysine demethylase 1A |
- HDACs deacetylate histones
- HDMs demethylate histones
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- Factors involved in megakaryocyte development and platelet production
|
|
|
KIF1C |
kinesin family member 1C |
- COPI-dependent Golgi-to-ER retrograde traffic
- Kinesins
|
|
|
KLF1 |
Kruppel like factor 1 |
|
|
- Congenital dyserythropoietic anemias (CDAs)
|
LAMC3 |
laminin subunit gamma 3 |
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- MET activates PTK2 signaling
|
|
|
LGALS3 |
galectin 3 |
- Neutrophil degranulation
- Advanced glycosylation endproduct receptor signaling
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
- RUNX2 regulates genes involved in differentiation of myeloid cells
|
- 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide
- Lactose
|
|
MAF1 |
MAF1 homolog, negative regulator of RNA polymerase III |
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
|
|
|
MAPK14 |
mitogen-activated protein kinase 14 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- DSCAM interactions
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- CD163 mediating an anti-inflammatory response
|
- Dasatinib
- 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
- N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
|
|
MDM2 |
MDM2 proto-oncogene |
- AKT phosphorylates targets in the cytosol
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- Trafficking of AMPA receptors
- Constitutive Signaling by AKT1 E17K in Cancer
- Ub-specific processing proteases
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Methylation
- Stabilization of p53
- Regulation of RUNX3 expression and activity
|
- Zinc
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
- Choriocarcinoma
- Osteosarcoma
- Glioma
- Penile cancer
- Alveolar rhabdomyosarcoma
|
MGMT |
O-6-methylguanine-DNA methyltransferase |
- MGMT-mediated DNA damage reversal
|
- L-Cysteine
- Zinc
- S-Methylcysteine
- Benzylcysteine
- Dinitrochlorobenzene
|
|
MS4A1 |
membrane spanning 4-domains A1 |
|
- Rituximab
- Ibritumomab tiuxetan
- Tositumomab
- Ofatumumab
- Obinutuzumab
- Ocrelizumab
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
|
|
- Choriocarcinoma
- Penile cancer
- Burkitt lymphoma
- Oral cancer
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Multiple myeloma
- Small cell lung cancer
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Osteosarcoma
- Kaposi's sarcoma
- Laryngeal cancer
- Breast cancer
- Ovarian cancer
|
MYCN |
MYCN proto-oncogene, bHLH transcription factor |
|
|
- Neuroblastoma
- Feingold syndrome
|
MYF5 |
myogenic factor 5 |
|
|
|
NAP1L4 |
nucleosome assembly protein 1 like 4 |
|
|
|
NCL |
nucleolin |
- Major pathway of rRNA processing in the nucleolus and cytosol
|
|
|
NR1D2 |
nuclear receptor subfamily 1 group D member 2 |
- Nuclear Receptor transcription pathway
|
|
|
P4HB |
prolyl 4-hydroxylase subunit beta |
- Collagen biosynthesis and modifying enzymes
- Detoxification of Reactive Oxygen Species
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Hedgehog ligand biogenesis
- VLDL assembly
- Post-translational protein phosphorylation
- Chylomicron assembly
- Interleukin-12 signaling
- Interleukin-23 signaling
|
|
|
PAK1 |
p21 (RAC1) activated kinase 1 |
- Generation of second messenger molecules
- Regulation of actin dynamics for phagocytic cup formation
- FCERI mediated MAPK activation
- FCERI mediated MAPK activation
- DSCAM interactions
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- Ephrin signaling
- Sema3A PAK dependent Axon repulsion
- Activation of RAC1
- Signal transduction by L1
- Smooth Muscle Contraction
- VEGFR2 mediated vascular permeability
- CD209 (DC-SIGN) signaling
- RHO GTPases activate PKNs
- RHO GTPases Activate ROCKs
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- MAPK6/MAPK4 signaling
- G beta:gamma signalling through CDC42
|
|
|
PIN1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
- ISG15 antiviral mechanism
- RHO GTPases Activate NADPH Oxidases
- Regulation of TP53 Activity through Phosphorylation
- PI5P Regulates TP53 Acetylation
- Negative regulators of DDX58/IFIH1 signaling
|
- Beta-(2-Naphthyl)-Alanine
- 3,6,9,12,15,18-HEXAOXAICOSANE
|
|
PIN4 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 4 |
|
|
|
PPP1R1B |
protein phosphatase 1 regulatory inhibitor subunit 1B |
- DARPP-32 events
- DARPP-32 events
|
|
|
PPP1R2 |
protein phosphatase 1 regulatory inhibitor subunit 2 |
|
|
|
PPP1R8 |
protein phosphatase 1 regulatory subunit 8 |
|
|
|
PRNP |
prion protein |
- NCAM1 interactions
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
|
|
- Prion diseases; Creutzfeldt-Jacob disease (CJD); Gerstmann-Straussler disease (GSD); Gerstmann-Straussler-Scheinker disease (GSSD); Fatal familial insomnia (FFI)
|
PTEN |
phosphatase and tensin homolog |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Negative regulation of the PI3K/AKT network
- Downstream TCR signaling
- TP53 Regulates Metabolic Genes
- PTEN Loss of Function in Cancer
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Regulation of PTEN mRNA translation
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Transcriptional Regulation by MECP2
|
|
- Vulvar cancer
- Prostate cancer
- Endometrial Cancer
- Glioma
- Small cell lung cancer
- Breast cancer
- Hepatocellular carcinoma
- Malignant melanoma
|
PTPN1 |
protein tyrosine phosphatase non-receptor type 1 |
- Integrin signaling
- Negative regulation of MET activity
- Regulation of IFNG signaling
- PTK6 Down-Regulation
- MECP2 regulates neuronal receptors and channels
- Regulation of IFNA signaling
- Growth hormone receptor signaling
- Growth hormone receptor signaling
|
- Tiludronic acid
- 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
- Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide
- Compound 9
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
- [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
- 2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid
- Compound 19
- Sp7343-Sp7964
- 2-(Oxalyl-Amino)-Benzoic Acid
- {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
- Novo Nordisk a/S Compound
- N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid
- 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- PNU177836
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
- 4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid
- N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid
- Cysteinesulfonic Acid
- 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
- 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid
- Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
- 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
- N-(Allyloxycarbonyl)-4-[N-(Carboxy-Formyl)-2-(Benzoic Acid)-Amino]-L-Phenylalaninyl-Amino-Butyloxy-(6-Hydroxy-Benzoic Acid Methyl Ester)
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
- [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
- {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
- 2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid
- 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
- ISIS 113715
- 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
- [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
- 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
- 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
- [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
- 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
- 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
- 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
- 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
- N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
- [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
- 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
- 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
- ISOTHIAZOLIDINONE ANALOG
- 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
- PARA-(BENZOYL)-PHENYLALANINE
- 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
- (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
- 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
- (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
|
|
PTPRC |
protein tyrosine phosphatase receptor type C |
- Phosphorylation of CD3 and TCR zeta chains
- Other semaphorin interactions
- Neutrophil degranulation
|
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
RAD1 |
RAD1 checkpoint DNA exonuclease |
- Activation of ATR in response to replication stress
- HDR through Single Strand Annealing (SSA)
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
|
|
|
RAD9A |
RAD9 checkpoint clamp component A |
- Activation of ATR in response to replication stress
- HDR through Single Strand Annealing (SSA)
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
|
|
|
RELA |
RELA proto-oncogene, NF-kB subunit |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NF-kB is activated and signals survival
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated NF-kB activation
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- PKMTs methylate histone lysines
- Transcriptional regulation of white adipocyte differentiation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Interleukin-1 processing
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- CD209 (DC-SIGN) signaling
- CLEC7A/inflammasome pathway
- The NLRP3 inflammasome
- Transcriptional Regulation by VENTX
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- Purinergic signaling in leishmaniasis infection
|
|
|
RGS19 |
regulator of G protein signaling 19 |
- G alpha (q) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- G alpha (z) signalling events
|
|
|
SAT1 |
spermidine/spermine N1-acetyltransferase 1 |
- Interconversion of polyamines
|
- N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine
|
- Keratosis follicularis spinulosa decalvans
|
SLC18A2 |
solute carrier family 18 member A2 |
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Na+/Cl- dependent neurotransmitter transporters
|
- Amphetamine
- Reserpine
- Norepinephrine
- Haloperidol
- Mazindol
- Benzphetamine
- Dopamine
- Deserpidine
- Ephedra
- Ephedrine
- MMDA
- Midomafetamine
- 4-Methoxyamphetamine
- Dextroamphetamine
- Methamphetamine
- Nomifensine
- Tetrabenazine
- Histamine
- Isometheptene
- Propylhexedrine
- Rauwolfia serpentina root
|
|
SMURF1 |
SMAD specific E3 ubiquitin protein ligase 1 |
- Signaling by BMP
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Asymmetric localization of PCP proteins
- Hedgehog 'on' state
- Hedgehog 'on' state
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Regulation of RUNX3 expression and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
SNCA |
synuclein alpha |
|
|
- Lewy body dementia (LBD); Dementia with Lewy bodies (DLB)
- Parkinson's disease (PD)
|
SNX6 |
sorting nexin 6 |
|
|
|
SPIB |
Spi-B transcription factor |
|
|
|
SPP1 |
secreted phosphoprotein 1 |
- Degradation of the extracellular matrix
- Signaling by PDGF
- Integrin cell surface interactions
- Integrin cell surface interactions
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- RUNX3 Regulates Immune Response and Cell Migration
- Post-translational protein phosphorylation
|
|
|
STX1A |
syntaxin 1A |
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- Glutamate Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Acetylcholine Neurotransmitter Release Cycle
- Insulin processing
- Regulation of insulin secretion
- Other interleukin signaling
- Toxicity of botulinum toxin type C (BoNT/C)
- LGI-ADAM interactions
- Neurexins and neuroligins
- GABA synthesis, release, reuptake and degradation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
|
|
|
TCF7L2 |
transcription factor 7 like 2 |
- Formation of the beta-catenin:TCF transactivating complex
- Formation of the beta-catenin:TCF transactivating complex
- Deactivation of the beta-catenin transactivating complex
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
- Ca2+ pathway
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- Repression of WNT target genes
- Repression of WNT target genes
- TCF7L2 mutants don't bind CTBP
- Transcriptional Regulation by VENTX
- RUNX3 regulates WNT signaling
|
|
- Type II diabetes mellitus
|
TCOF1 |
treacle ribosome biogenesis factor 1 |
|
|
- Treacher Collins syndrome
|
TGFBR1 |
transforming growth factor beta receptor 1 |
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- UCH proteinases
- Ub-specific processing proteases
|
- 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
- Naphthyridine Inhibitor
- 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
- N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
- 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
- N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
|
- Loeys-Dietz syndrome (LDS)
- Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
|
TGM2 |
transglutaminase 2 |
|
|
|
TOP1 |
DNA topoisomerase I |
- SUMOylation of DNA replication proteins
|
- Irinotecan
- Topotecan
- Camptothecin
- Edotecarin
- Lucanthone
- Elsamitrucin
- 7-ethyl-10-hydroxycamptothecin
- Sodium stibogluconate
- Cositecan
- XMT-1001
- 2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM
- 4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE
|
|
TP53 |
tumor protein p53 |
- Activation of NOXA and translocation to mitochondria
- Activation of PUMA and translocation to mitochondria
- Pre-NOTCH Transcription and Translation
- Oxidative Stress Induced Senescence
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- Oncogene Induced Senescence
- DNA Damage/Telomere Stress Induced Senescence
- SUMOylation of transcription factors
- Autodegradation of the E3 ubiquitin ligase COP1
- Association of TriC/CCT with target proteins during biosynthesis
- TP53 Regulates Metabolic Genes
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Interleukin-4 and Interleukin-13 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
- TP53 Regulates Transcription of Caspase Activators and Caspases
- TP53 Regulates Transcription of Death Receptors and Ligands
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
- Regulation of TP53 Expression
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- Regulation of TP53 Activity through Methylation
- PI5P Regulates TP53 Acetylation
- G2/M DNA damage checkpoint
- G2/M Checkpoints
- Stabilization of p53
- Transcriptional activation of cell cycle inhibitor p21
- The role of GTSE1 in G2/M progression after G2 checkpoint
- Transcriptional Regulation by VENTX
- RUNX3 regulates CDKN1A transcription
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Factors involved in megakaryocyte development and platelet production
|
- Acetylsalicylic acid
- Zinc
- Triethyl Phosphate
- AZD 3355
- 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
|
- Osteosarcoma
- Adrenal carcinoma
- Thyroid cancer
- Breast cancer
- Basal cell carcinoma
- Malignant melanoma
- Pancreatic cancer
- Gastric cancer
- Malignant pleural mesothelioma
- Non-small cell lung cancer
- Esophageal cancer
- Oral cancer
- Multiple myeloma
- Small cell lung cancer
- Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
- Glioma
- Squamous cell carcinoma
- Kaposi's sarcoma
- Cholangiocarcinoma
- Gallbladder cancer
- Cancer of the anal canal
- Hepatocellular carcinoma
- Choriocarcinoma
- Vulvar cancer
- Choroid plexus papilloma
- Burkitt lymphoma
- Adult T-cell leukemia
- Hairy-cell leukemia
- Bladder cancer
- Chronic lymphocytic leukemia (CLL)
- Penile cancer
- Endometrial Cancer
- Ovarian cancer
- Colorectal cancer
- Laryngeal cancer
- Chronic myeloid leukemia (CML)
|
TP63 |
tumor protein p63 |
- Activation of PUMA and translocation to mitochondria
- TP53 Regulates Metabolic Genes
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
- TP53 Regulates Transcription of Caspase Activators and Caspases
- TP53 Regulates Transcription of Death Receptors and Ligands
- Regulation of TP53 Activity through Association with Co-factors
|
|
- Limb-mammary syndrome
- ADULT syndrome
- Split-hand/foot malformation (SHFM)
- Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
- Ectrodactyly-ectodermal dysplasia cleft-palate syndrome (EEC syndrome)
- Ankyloblepharon-ctodermal defects-cleft lip/palate (AEC) syndrome and Rapp-Hodgkin syndrome
|
TRIM41 |
tripartite motif containing 41 |
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
TTLL12 |
tubulin tyrosine ligase like 12 |
- Carboxyterminal post-translational modifications of tubulin
|
|
|
UBE2R2 |
ubiquitin conjugating enzyme E2 R2 |
- Synthesis of active ubiquitin: roles of E1 and E2 enzymes
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
WAS |
WASP actin nucleation promoting factor |
- Generation of second messenger molecules
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
|
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
- Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM)
- Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia
|
XRCC1 |
X-ray repair cross complementing 1 |
- Resolution of AP sites via the single-nucleotide replacement pathway
- APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
- HDR through MMEJ (alt-NHEJ)
- Gap-filling DNA repair synthesis and ligation in GG-NER
- Gap-filling DNA repair synthesis and ligation in TC-NER
|
|
|
ZNF219 |
zinc finger protein 219 |
|
|
|
ZNF423 |
zinc finger protein 423 |
|
|
- Systemic lupus erythematosus
|
ZNF670 |
zinc finger protein 670 |
- Generic Transcription Pathway
|
|
|
ZNHIT3 |
zinc finger HIT-type containing 3 |
|
|
|